The makers of rapid antigen tests have hit back at claims of inaccurate COVID-19 results, blaming a lack of education about how and when to use the tests.
Pathology Technology Australia, the peak body for test manufacturers and suppliers, defended the performance of rapid tests against new variants of Omicron, accusing critics of "fearmongering".
"Nothing has changed, we're yet to see any evidence that clearly indicates performance has been impacted by the sub-variants," chief executive Dean Whiting said in a statement.